MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1055/a-1664-1164

Медицинская библиотека · TH open : companion journal to thrombosis and haemostasis · 2021

Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT).

Fukuda Ikuo, Hirayama Atsushi, Kawasugi Kazuo, Kobayashi Takao, Maeda Hideaki, Nakamura Mashio, Nakanishi Norifumi, Yamada Norikazu, Tajima Tsubasa, Iwashiro Sanghun, Okayama Yutaka, Sunaya Toshiyuki, Hirano Kazufumi, Hayasaki Takanori

СтатьяПеревод в очереди

Аннотация

Background  The efficacy and safety of rivaroxaban have been demonstrated in phase 3 trials of patients with venous thromboembolism (VTE; pulmonary embolism [PE] and deep vein thrombosis [DVT]). Data regarding rivaroxaban treatment of VTE in routine Japanese clinical practice remain limited. Objectives  XASSENT will evaluate rivaroxaban treatment of VTE in real-world Japanese clinical practice. We report the study design and baseline patient characteristics. Methods  XASSENT (NCT02558465) is an open-label, prospective observational, post-marketing surveillance cohort study in patients receiving rivaroxaban treatment for VTE. Enrolment took place between November 2015 and March 2018. XASSENT will follow patients for up to 2 years. Primary outcome variables: major bleeding and symptomatic recurrent VTE. Statistical analyses are exploratory and descriptive. Results  Baseline patient characteristics at June 2020 ( n  = 2,299) are presented (58.2% female; mean age 66.7 years; mean weight 60.9 kg). The population encompasses patients with wide-ranging characteristics including older age, low weight, and renal dysfunction. Most participants (67.6%) had a history of VTE risk factors at baseline. Half of the population (50.4%) had DVT only; 41.4% had DVT with PE; 8.2% had PE only. Overall, 68.4% were inpatients and 77.1% had symptomatic VTE. Rivaroxaban was prescribed for initial treatment in 84.6% of patients and maintenance treatment in 15.4%. Most were prescribed the approved dose of rivaroxaban for initial (30 mg daily; 84.4%) or maintenance (15 mg daily; 81.9%) treatment of VTE in Japan. The most common reason for selecting non-recommended dose was 'elderly'. Conclusions  Results from XASSENT will complement phase 3 trial data and inform clinical practice.

Для цитирования: Fukuda Ikuo, Hirayama Atsushi, Kawasugi Kazuo, Kobayashi Takao, Maeda Hideaki, Nakamura Mashio, Nakanishi Norifumi, Yamada Norikazu, Tajima Tsubasa, Iwashiro Sanghun, Okayama Yutaka, Sunaya Toshiyuki, Hirano Kazufumi, Hayasaki Takanori. Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT).. TH open : companion journal to thrombosis and haemostasis. 2021. DOI: 10.1055/a-1664-1164.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.